Semaglutide in Canada: Ozempic, Wegovy, Rybelsus, Sevmia and the generics
Product by product: the Canadian indication, the population, the authorized versus marketed status, the presentation and the monograph.
Semaglutide is one ingredient sold in Canada under several product names, for different conditions, in different presentations, with different regulatory statuses. Mixing them up is the most common mistake in the questions this site was built to answer. This page maps ingredient to product to indication, from the current Health Canada Drug Product Database records and product monographs.
Paraphrases below come from each product's Canadian monograph as linked from its DPD record. They are not dosing guidance and not an eligibility check. A US indication is never carried over to a Canadian product.
The short version
Ozempic and the generic injections (Apotex, Dr. Reddy's, two Aspen products and, since 16 September 2026, Sandoz) are for type 2 diabetes. None has a Canadian weight-management indication. R43-C12 The generic semaglutide page lists them with Ontario prices and recalls.
Wegovy is for chronic weight management (adults, and adolescents 12 to under 18), for reducing non-fatal heart attack risk in adults with established cardiovascular disease, and conditionally for MASH.
Sevmia (Apotex) is the first generic semaglutide for chronic weight management, authorized 29 June 2026. Its DPD status is Approved, not Marketed, and it comes as one pen delivering 1 mg doses only. The monograph says other doses need other products.
Rybelsus is the oral tablet, for type 2 diabetes, with a cardiovascular indication added at the end of 2025 and new 1.5, 4 and 9 mg strengths marketed in March 2026.
Plosbrio and Poviztra are additional product names for the Novo Nordisk biologics (Ozempic and Wegovy respectively), approved but not marketed. They are not generics.
Two Aspen products and the Sandoz product are Approved but not Marketed. Four recalls of Dr. Reddy's and Apotex pens since August 2026 did not change their DPD status; they are listed on the generic semaglutide page. R43-C14R43-C15R43-C16
At a glance
Semaglutide products in Canada at a glance, from each product's DPD record and monograph
Adults: type 2 diabetes glycemic control; reduction of major adverse cardiovascular events with established cardiovascular disease and/or chronic kidney disease; renal and cardiovascular risk reduction with type 2 diabetes plus chronic kidney disease. Not a weight-management indication. R21-C459A-C04
Chronic weight management: adults with BMI 30 or more, or 27 or more with a weight-related condition; ages 12 to under 18 with BMI at or above the 95th percentile, body weight above 60 kg and inadequate response to diet and activity. Adult reduction of non-fatal myocardial infarction risk with established cardiovascular disease and BMI 27 or more. Adult non-cirrhotic MASH with fibrosis F2 to F3 under conditional authorization (NOC/c). R21-C434R21-C435R21-C449R21-C450A-C03
Marketed (multidose pens); Approved, not marketed (single-dose pens)
Multidose pens marketed 2024-03-28 to 2026-08-27; single-dose pens approved 2021-11-23
Adult type 2 diabetes glycemic control alongside diet and exercise; alone if metformin is inappropriate, or combined with other diabetes medicines. Also reduces cardiovascular death, non-fatal MI or stroke in adults with type 2 diabetes and established cardiovascular disease or high event risk. Not a weight-management indication. R21-C424R21-C425R21-C437A-C05
Chronic weight management: adults with BMI 30 or more, or 27 or more with a comorbidity; ages 12 to under 18 with BMI at or above the 95th percentile, body weight above 60 kg and inadequate response to diet and activity. Adult reduction of non-fatal MI risk with established cardiovascular disease and BMI 27 or more. No MASH indication. R21-C432R21-C444A-C02
Adults: type 2 diabetes glycemic control; MACE reduction with established cardiovascular disease and/or chronic kidney disease; kidney and cardiovascular risk reduction with chronic kidney disease. Not a weight-management indication. R21-C457R21-C445A-C12
Approved (not Marketed)
2025-12-22 (02568233 and 02568241 approved 2026-05-11)
Chronic weight management: adults with BMI 30 or more, or 27 or more with a comorbidity; ages 12 to under 18 with BMI at or above the 95th percentile, body weight above 60 kg and inadequate response to diet and activity. Adult reduction of non-fatal MI risk with established cardiovascular disease and BMI 27 or more. No MASH indication shown. R21-C458R21-C446A-C12
Approved (not Marketed)
2025-12-22
A DPD status says whether a product is authorized and whether the company reports it as sold. It does not say whether a pharmacy has it, whether a plan pays for it, or whether it suits anyone. Coverage is on the coverage page.
Health Canada authorizes a product and issues a DIN. The DPD then records whether it is Marketed, Approved (authorized but not yet sold), Dormant or Cancelled. None of that says whether a pharmacy has it. Public coverage and interchangeability are provincial decisions made after all of this. See the coverage record.
Product records
Ozempic (semaglutide; Novo Nordisk Canada Inc; brand)
Canadian record for Ozempic
Canadian indication (paraphrase of the product monograph)
Adults: type 2 diabetes glycemic control; reduction of major adverse cardiovascular events with established cardiovascular disease and/or chronic kidney disease; renal and cardiovascular risk reduction with type 2 diabetes plus chronic kidney disease. Not a weight-management indication. R21-C459A-C04
Unknown. Not researched by design; regulatory status never populates stock.
Note
Ozempic has no Canadian weight-management indication. Provincial public plans cover it only for type 2 diabetes with criteria.
Wegovy (semaglutide; Novo Nordisk Canada Inc; brand)
Canadian record for Wegovy
Canadian indication (paraphrase of the product monograph)
Chronic weight management: adults with BMI 30 or more, or 27 or more with a weight-related condition; ages 12 to under 18 with BMI at or above the 95th percentile, body weight above 60 kg and inadequate response to diet and activity. Adult reduction of non-fatal myocardial infarction risk with established cardiovascular disease and BMI 27 or more. Adult non-cirrhotic MASH with fibrosis F2 to F3 under conditional authorization (NOC/c). R21-C434R21-C435R21-C449R21-C450A-C03
Population
Adults; adolescents 12 to under 18 for weight management
Multidose FlexTouch pens delivering 0.25, 0.5, 1, 1.7 or 2.4 mg (Marketed); single-dose pens 0.25 to 2.4 mg (Approved, not marketed)
Authorization notes
Weight management and MI indications: full authorization. MASH: NOC/c, on the conditions list without a conditions-met notation; confirmatory ESSENCE report expected 2029.
Unknown. Not researched by design; regulatory status never populates stock.
Note
Wegovy is the Canadian reference product for Sevmia.
Rybelsus (semaglutide; Novo Nordisk Canada Inc; brand)
Canadian record for Rybelsus
Canadian indication (paraphrase of the product monograph)
Adult type 2 diabetes glycemic control alongside diet and exercise; alone if metformin is inappropriate, or combined with other diabetes medicines. Also reduces cardiovascular death, non-fatal MI or stroke in adults with type 2 diabetes and established cardiovascular disease or high event risk. Not a weight-management indication. R21-C424R21-C425R21-C437A-C05
Canadian indication (paraphrase of the product monograph)
Chronic weight management: adults with BMI 30 or more, or 27 or more with a comorbidity; ages 12 to under 18 with BMI at or above the 95th percentile, body weight above 60 kg and inadequate response to diet and activity. Adult reduction of non-fatal MI risk with established cardiovascular disease and BMI 27 or more. No MASH indication. R21-C432R21-C444A-C02
Population
Adults; adolescents 12 to under 18
DPD status (authorized versus marketed)
Approved (not Marketed) Status date: 2026-06-29R21-C378
DINs
02569582
Presentation
One multidose prefilled pen, 4 mg/3 mL, delivering 1 mg doses only; four doses and four needles
Authorization notes
Abbreviated new drug submission (NOC 37782) with Wegovy as the Canadian reference product; no conditions.
Unknown. Not researched by design; regulatory status never populates stock.
Note
The monograph says other products are needed for doses other than 1 mg. Do not price a treatment course from this product. DPD status Approved does not mean it is on pharmacy shelves.
Unknown. Not researched by design; regulatory status never populates stock.
Plosbrio (semaglutide; Novo Nordisk Canada Inc; brand (additional product name))
Canadian record for Plosbrio
Canadian indication (paraphrase of the product monograph)
Adults: type 2 diabetes glycemic control; MACE reduction with established cardiovascular disease and/or chronic kidney disease; kidney and cardiovascular risk reduction with chronic kidney disease. Not a weight-management indication. R21-C457R21-C445A-C12
Unknown. Not researched by design; regulatory status never populates stock.
Poviztra (semaglutide; Novo Nordisk Canada Inc; brand (additional product name))
Canadian record for Poviztra
Canadian indication (paraphrase of the product monograph)
Chronic weight management: adults with BMI 30 or more, or 27 or more with a comorbidity; ages 12 to under 18 with BMI at or above the 95th percentile, body weight above 60 kg and inadequate response to diet and activity. Adult reduction of non-fatal MI risk with established cardiovascular disease and BMI 27 or more. No MASH indication shown. R21-C458R21-C446A-C12
Not authorized; submission accepted for review January 2026 Status date: 2026-09-24 (review list checked)
DINs
none
Presentation
Oral; not authorized in Canada
Authorization notes
On Health Canada's submissions under review list (accepted 2026-01; list modified 2026-09-24). US FDA approved it as Foundayo on 2026-04-01 for weight management; a US approval does not apply in Canada. One published profile says the Canadian submission is for type 2 diabetes.
Not authorized; submission accepted for review March 2026 Status date: 2026-03
DINs
none
Presentation
Not authorized in Canada
Authorization notes
On Health Canada's submissions under review list (accepted 2026-03). Novo Nordisk expects a US FDA decision in the fourth quarter of 2026. In REDEFINE 4 it did not meet its non-inferiority goal against tirzepatide.
Unknown. Not researched by design; regulatory status never populates stock.
(none) (retatrutide; Eli Lilly; investigational)
Canadian record for (none)
Canadian indication (paraphrase of the product monograph)
No Canadian indication. Health Canada's unauthorized peptide alert (2026-04-09) names retatrutide. A-C13A-C14R43-C05R43-C06
Population
not applicable
DPD status (authorized versus marketed)
Investigational; not authorized Status date: 2026-08-13 (company statement)
DINs
none
Presentation
Not authorized in Canada
Authorization notes
Not approved anywhere and not on Health Canada's review list (2026-09-24). Lilly plans a US FDA submission in early 2027. Health Canada warns about fake and unauthorized GLP-1 products (2026-01-21).
Not advice; a list of things worth asking about, drawn from the monographs and Health Canada notices: contraindications specific to each product; the aspiration-risk review for GLP-1 therapies before general anesthesia or deep sedation; what happens to weight after stopping (see the stopping and weight regain studies); and how the indication on the label matches the reason for the prescription. A-C42
Common questions
Is Ozempic approved for weight loss in Canada?
No. Ozempic is authorized for type 2 diabetes and for heart and kidney risk reduction in people with diabetes; none of these is a weight-management indication R21-C459. The semaglutide product authorized for chronic weight management is Wegovy R21-C434.
What is the difference between Ozempic and Wegovy?
Both are semaglutide. Ozempic is for type 2 diabetes R21-C459; Wegovy is for chronic weight management in adults and in adolescents 12 and up, for reducing non-fatal heart attack risk in adults with established cardiovascular disease, and conditionally for MASH R21-C434R21-C435. Their dose ranges and pens differ too.
Is there a generic Wegovy in Canada?
Sevmia (Apotex) was authorized on 29 June 2026 as a generic of Wegovy for chronic weight management R21-C432R21-C444. Its status in Health Canada's database is Approved, not Marketed, and the one pen gives 1 mg doses only. The generics on pharmacy shelves so far copy Ozempic and are for type 2 diabetes; see the generic semaglutide page.
Are Plosbrio and Poviztra generics?
No. They are additional product names from Novo Nordisk for the same medicines as Ozempic and Wegovy, approved but not marketed R21-C457R21-C458.
Does any public drug plan cover semaglutide for weight loss?
No province or territory reviewed on this site lists Wegovy, Sevmia or Ozempic for weight management on its public plan. Ozempic and the generics are listed for type 2 diabetes, with criteria; see the coverage record. Private plan forms are on the prior authorization forms page.
Sources for this page
Every claim ID below is a row in the evidence ledger. The source date is the date the source itself carries; the access date is when the researcher opened it. A claim with several rows is one claim with several sources, not several confirmations.
This table scrolls sideways.
Source records for every claim cited on this page
Claim
What the source says
Source
Source date
Accessed
Label
R43-C12
Health Canada authorized Sandoz generic semaglutide (DINs 02571501 and 02571528) on 2026-09-16; Sandoz gave no launch date.
Adults: type 2 diabetes glycemic control; MACE reduction with established CVD and/or CKD; renal/CV risk reduction with type 2 diabetes plus CKD. No pediatric indication. These are not weight-management indications.
Weight management: adults BMI ≥30, or ≥27 plus comorbidity; ages 12 to <18 with BMI ≥95th percentile, >60 kg and inadequate diet/activity response. Adult nonfatal-MI reduction: established CVD/BMI ≥27. Adult noncirrhotic MASH, fibrosis F2, F3, is conditional.
Adult type 2 diabetes: glycemic control alongside diet/exercise; alone if metformin is inappropriate, or combined with other diabetes medicines. Also reduces CV death, nonfatal MI or stroke in adults with type 2 diabetes and established CVD or high event risk. No pediatric indication.
Weight management: adults BMI ≥30, or ≥27 plus comorbidity; ages 12 to <18 with BMI ≥95th percentile, >60 kg and inadequate diet/activity response. Adult nonfatal-MI risk reduction: established CVD and BMI ≥27.
Recall RA-82537 includes both DINs: 02567806 lots 7000544/7000545/7000546; 02567814 lots 7000542/7000543/7000624/7000628/7000629. DPD still says Marketed. The notice reports an impurity outside specifications; Type II retail recall.
Adults: type 2 diabetes glycemic control; MACE reduction with established CVD and/or CKD; sustained eGFR-decline, end-stage-kidney-disease and CV-death risk reduction with CKD. No pediatric indication. Multidose pens deliver 0.25/0.5, 1 or 2 mg.
Health Canada's new drug submissions under review list shows orforglipron calcium, therapeutic area Drugs used in diabetes, accepted for review in January 2026, sponsor Eli Lilly Canada Inc.
No orforglipron product appears in the Health Canada Drug Product Database or the Notice of Compliance database as of 2026-10-01; it is not authorized in Canada.
A peer-reviewed drug profile (Drugs, 2026-07-21) reports that orforglipron was submitted in the EU for long-term weight management and type 2 diabetes, in Japan for weight management, and in Canada for type 2 diabetes.
The US FDA approved orforglipron as Foundayo on 2026-04-01 for adults with obesity, or overweight with weight-related medical problems, with diet and exercise; tablets of 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg. Lilly says it has submitted orforglipron in more than 40 countries and plans to launch in each shortly after approval.
Health Canada's submissions under review list shows cagrilintide and semaglutide (CagriSema), therapeutic area Drugs used in diabetes, accepted for review in March 2026, sponsor Novo Nordisk Canada Inc.